Apparel - Manufacturers
Compare Stocks
5 / 10Stock Comparison
VNCE vs CURV vs XPOF vs RCUS vs VRA
Revenue, margins, valuation, and 5-year total return — side by side.
Apparel - Retail
Leisure
Biotechnology
Apparel - Footwear & Accessories
VNCE vs CURV vs XPOF vs RCUS vs VRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Apparel - Manufacturers | Apparel - Retail | Leisure | Biotechnology | Apparel - Footwear & Accessories |
| Market Cap | $61M | $160M | $244M | $2.50B | $116M |
| Revenue (TTM) | $296M | $1.00B | $299M | $236M | $270M |
| Net Income (TTM) | $-18M | $-7M | $-34M | $-369M | $-48M |
| Gross Margin | 50.0% | 34.8% | 83.2% | 90.7% | 46.4% |
| Operating Margin | -5.9% | 2.1% | 7.8% | -168.6% | -12.0% |
| Forward P/E | — | — | 10.9x | — | — |
| Total Debt | $122M | $149M | $525M | $99M | $71M |
| Cash & Equiv. | $607K | $20M | $46M | $222M | $19M |
VNCE vs CURV vs XPOF vs RCUS vs VRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Vince Holding Corp. (VNCE) | 100 | 60.0 | -40.0% |
| Torrid Holdings Inc. (CURV) | 100 | 6.6 | -93.4% |
| Xponential Fitness,… (XPOF) | 100 | 55.8 | -44.2% |
| Arcus Biosciences, … (RCUS) | 100 | 78.9 | -21.1% |
| Vera Bradley, Inc. (VRA) | 100 | 37.6 | -62.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VNCE vs CURV vs XPOF vs RCUS vs VRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VNCE is the #2 pick in this set and the best alternative if growth and value is your priority.
- 0.2% revenue growth vs VRA's -27.5%
- Better valuation composite
CURV carries the broadest edge in this set and is the clearest fit for quality and stability.
- -0.7% margin vs RCUS's -156.4%
- Beta 0.46 vs VNCE's 2.42
- -1.7% ROA vs RCUS's -35.3%, ROIC 22.5% vs -64.1%
XPOF ranks third and is worth considering specifically for growth exposure.
- Rev growth -1.7%, EPS growth 35.2%, 3Y rev CAGR 9.0%
- 2.5% yield; the other 4 pay no meaningful dividend
RCUS is the clearest fit if your priority is long-term compounding.
- 45.9% 10Y total return vs XPOF's -46.6%
- +209.6% vs CURV's -70.9%
VRA is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 3 yrs, beta 1.25
- Lower volatility, beta 1.25, Low D/E 53.6%, current ratio 2.37x
- Beta 1.25, current ratio 2.37x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 0.2% revenue growth vs VRA's -27.5% | |
| Value | Better valuation composite | |
| Quality / Margins | -0.7% margin vs RCUS's -156.4% | |
| Stability / Safety | Beta 0.46 vs VNCE's 2.42 | |
| Dividends | 2.5% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +209.6% vs CURV's -70.9% | |
| Efficiency (ROA) | -1.7% ROA vs RCUS's -35.3%, ROIC 22.5% vs -64.1% |
VNCE vs CURV vs XPOF vs RCUS vs VRA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VNCE vs CURV vs XPOF vs RCUS vs VRA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VNCE leads in 1 of 6 categories
CURV leads 1 • XPOF leads 1 • RCUS leads 1 • VRA leads 1 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
VNCE leads this category, winning 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CURV is the larger business by revenue, generating $1.0B annually — 4.2x RCUS's $236M. CURV is the more profitable business, keeping -0.7% of every revenue dollar as net income compared to RCUS's -156.4%. On growth, VNCE holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $296M | $1.0B | $299M | $236M | $270M |
| EBITDAEarnings before interest/tax | -$16M | $75M | $35M | -$391M | -$4M |
| Net IncomeAfter-tax profit | -$18M | -$7M | -$34M | -$369M | -$48M |
| Free Cash FlowCash after capex | $13M | -$22M | -$3M | -$489M | $10M |
| Gross MarginGross profit ÷ Revenue | +50.0% | +34.8% | +83.2% | +90.7% | +46.4% |
| Operating MarginEBIT ÷ Revenue | -5.9% | +2.1% | +7.8% | -168.6% | -12.0% |
| Net MarginNet income ÷ Revenue | -6.2% | -0.7% | -11.3% | -156.4% | -17.7% |
| FCF MarginFCF ÷ Revenue | +4.3% | -2.2% | -1.1% | -2.1% | +3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.2% | -14.3% | -21.0% | -39.3% | -15.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -38.2% | -185.7% | +79.1% | +10.5% | +105.3% |
Valuation Metrics
CURV leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, XPOF's 7.9x EV/EBITDA is more attractive than CURV's 13.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $61M | $160M | $244M | $2.5B | $116M |
| Enterprise ValueMkt cap + debt − cash | $183M | $290M | $723M | $2.4B | $168M |
| Trailing P/EPrice ÷ TTM EPS | -3.16x | -21.86x | -4.45x | -7.54x | -2.42x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 10.90x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 13.53x | 7.89x | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.21x | 0.16x | 0.78x | 10.11x | 0.43x |
| Price / BookPrice ÷ Book value/share | 1.44x | — | — | 4.22x | 0.90x |
| Price / FCFMarket cap ÷ FCF | 3.41x | — | 9.86x | — | 11.49x |
Profitability & Efficiency
XPOF leads this category, winning 3 of 9 comparable metrics.
Profitability & Efficiency
VNCE delivers a -34.4% return on equity — every $100 of shareholder capital generates $-34 in annual profit, vs $-69 for RCUS. RCUS carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to VNCE's 2.93x. On the Piotroski fundamental quality scale (0–9), VNCE scores 5/9 vs RCUS's 0/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -34.4% | — | — | -69.0% | -35.0% |
| ROA (TTM)Return on assets | -7.5% | -1.7% | -9.5% | -35.3% | -18.9% |
| ROICReturn on invested capital | -7.6% | +22.5% | +75.0% | -64.1% | -11.8% |
| ROCEReturn on capital employed | -11.0% | +11.4% | +30.3% | -42.1% | -15.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 | 5 | 0 | 4 |
| Debt / EquityFinancial leverage | 2.93x | — | — | 0.16x | 0.54x |
| Net DebtTotal debt minus cash | $122M | $129M | $479M | -$123M | $52M |
| Cash & Equiv.Liquid assets | $607,000 | $20M | $46M | $222M | $19M |
| Total DebtShort + long-term debt | $122M | $149M | $525M | $99M | $71M |
| Interest CoverageEBIT ÷ Interest expense | -4.94x | 0.84x | -0.24x | -13.38x | -71.04x |
Total Returns (Dividends Reinvested)
RCUS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $8,143 today (with dividends reinvested), compared to $634 for CURV. Over the past 12 months, RCUS leads with a +209.6% total return vs CURV's -70.9%. The 3-year compound annual growth rate (CAGR) favors RCUS at 7.7% vs XPOF's -39.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +13.8% | +44.3% | -18.5% | +6.5% | +60.5% |
| 1-Year ReturnPast 12 months | +182.2% | -70.9% | -22.6% | +209.6% | +120.2% |
| 3-Year ReturnCumulative with dividends | -21.2% | -60.1% | -77.4% | +24.9% | -22.3% |
| 5-Year ReturnCumulative with dividends | -60.3% | -93.7% | -46.6% | -18.6% | -62.5% |
| 10-Year ReturnCumulative with dividends | -91.9% | -93.7% | -46.6% | +45.9% | -75.1% |
| CAGR (3Y)Annualised 3-year return | -7.6% | -26.4% | -39.1% | +7.7% | -8.1% |
Risk & Volatility
Evenly matched — CURV and VRA each lead in 1 of 2 comparable metrics.
Risk & Volatility
CURV is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than VNCE's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRA currently trades 94.3% from its 52-week high vs CURV's 25.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.42x | 0.46x | 1.94x | 1.95x | 1.25x |
| 52-Week HighHighest price in past year | $5.90 | $6.08 | $11.14 | $28.72 | $4.39 |
| 52-Week LowLowest price in past year | $1.02 | $0.94 | $3.83 | $7.06 | $1.39 |
| % of 52W HighCurrent price vs 52-week peak | +80.8% | +25.2% | +58.7% | +86.3% | +94.3% |
| RSI (14)Momentum oscillator 0–100 | 64.1 | 35.2 | 48.4 | 60.5 | 61.4 |
| Avg Volume (50D)Average daily shares traded | 171K | 852K | 626K | 1.2M | 344K |
Analyst Outlook
VRA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CURV as "Hold", XPOF as "Buy", RCUS as "Buy", VRA as "Hold". Consensus price targets imply 22.3% upside for XPOF (target: $8) vs -1.3% for CURV (target: $2). XPOF is the only dividend payer here at 2.50% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $1.51 | $8.00 | $30.00 | — |
| # AnalystsCovering analysts | — | 10 | 14 | 18 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.5% | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | 0 | — | 3 |
| Dividend / ShareAnnual DPS | — | — | $0.16 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
VNCE leads in 1 of 6 categories (Income & Cash Flow). CURV leads in 1 (Valuation Metrics). 1 tied.
VNCE vs CURV vs XPOF vs RCUS vs VRA: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is VNCE or CURV or XPOF or RCUS or VRA a better buy right now?
For growth investors, Vince Holding Corp.
(VNCE) is the stronger pick with 0. 2% revenue growth year-over-year, versus -27. 5% for Vera Bradley, Inc. (VRA). Analysts rate Xponential Fitness, Inc. (XPOF) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VNCE or CURV or XPOF or RCUS or VRA?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -18. 6%, compared to -93. 7% for Torrid Holdings Inc. (CURV). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus CURV's -93. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VNCE or CURV or XPOF or RCUS or VRA?
By beta (market sensitivity over 5 years), Torrid Holdings Inc.
(CURV) is the lower-risk stock at 0. 46β versus Vince Holding Corp. 's 2. 42β — meaning VNCE is approximately 430% more volatile than CURV relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 3% for Vince Holding Corp. — giving it more financial flexibility in a downturn.
04Which is growing faster — VNCE or CURV or XPOF or RCUS or VRA?
By revenue growth (latest reported year), Vince Holding Corp.
(VNCE) is pulling ahead at 0. 2% versus -27. 5% for Vera Bradley, Inc. (VRA). On earnings-per-share growth, the picture is similar: Xponential Fitness, Inc. grew EPS 35. 2% year-over-year, compared to -174. 0% for Vince Holding Corp.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VNCE or CURV or XPOF or RCUS or VRA?
Torrid Holdings Inc.
(CURV) is the more profitable company, earning -0. 7% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps -0. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XPOF leads at 25. 3% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is VNCE or CURV or XPOF or RCUS or VRA more undervalued right now?
Analyst consensus price targets imply the most upside for XPOF: 22.
3% to $8. 00.
07Which pays a better dividend — VNCE or CURV or XPOF or RCUS or VRA?
In this comparison, XPOF (2.
5% yield) pays a dividend. VNCE, CURV, RCUS, VRA do not pay a meaningful dividend and should not be held primarily for income.
08Is VNCE or CURV or XPOF or RCUS or VRA better for a retirement portfolio?
For long-horizon retirement investors, Torrid Holdings Inc.
(CURV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46)). Vince Holding Corp. (VNCE) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CURV: -93. 7%, VNCE: -91. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between VNCE and CURV and XPOF and RCUS and VRA?
These companies operate in different sectors (VNCE (Consumer Cyclical) and CURV (Consumer Cyclical) and XPOF (Consumer Cyclical) and RCUS (Healthcare) and VRA (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
XPOF pays a dividend while VNCE, CURV, RCUS, VRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.